{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:03:36Z","timestamp":1784819016506,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant melanoma of the female genital tract is relatively uncommon and accounts for 3\u20137% of all melanoma localizations. This study aimed to identify driver genes in melanoma of the female genital tract with the purpose of enhancing understanding of disease pathogenesis and identifying potential new therapeutic targets to develop effective therapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>KIT (CD117) and BRAF expression were detected immunohistochemically. Polymerase Chain Reaction (PCR) and Sanger sequencing techniques were performed to identify the mutational status of <jats:italic>BRAF, NRAS, KRAS, NF1, KIT, PDGFRA<\/jats:italic> and <jats:italic>SF3B1<\/jats:italic> on 19 melanomas of the female genital tract, paired with 25 cutaneous melanomas, 18 acral melanomas and 11 melanomas of nasal cavity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Somatic variant analysis identified <jats:italic>KRAS<\/jats:italic> (6\/19; 32%) as the most commonly mutated gene, followed by <jats:italic>KIT<\/jats:italic> (4\/19; 21%), <jats:italic>SF3B1<\/jats:italic> (3\/19; 16%) and <jats:italic>NRAS<\/jats:italic> (1\/19; 5%). None of the cases were found to harbor <jats:italic>BRAF, NF1<\/jats:italic> and <jats:italic>PDGFRA<\/jats:italic> mutations in melanomas of the female genital tract. However, none of the cases were found to harbor <jats:italic>SF3B1<\/jats:italic> and <jats:italic>KIT<\/jats:italic> mutations in cutaneous melanomas, acral melanomas and melanomas of nasal cavity. Recurrent <jats:italic>KIT<\/jats:italic> mutations, as well as mutations in the less frequently mutated genes <jats:italic>NRAS<\/jats:italic> and <jats:italic>SF3B1,<\/jats:italic> were exclusively detected in vulvovaginal melanomas, but not in tumors arising in the cervix. However, recurrent <jats:italic>KRAS<\/jats:italic> mutations were detected in similar frequencies in tumors of the vulva, vagina, and cervix. Additionally, recurrent <jats:italic>KRAS<\/jats:italic> and <jats:italic>KIT<\/jats:italic> mutations occurred predominantly in polygonal and epithelioid cell types of melanoma in the female genital tract. Immunohistochemistry revealed moderate or strong cytoplasmic CD117 expression in 6 of the 19 cases (31.6%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We observed that gynecologic melanoma harbored distinct mutation rates in the <jats:italic>KIT, BRAF, SF3B1, KRAS, and NRAS<\/jats:italic> genes. Our findings support the notion that gynecologic melanoma is a distinct entity from non-gynecologic melanoma, and these findings offer insights into future therapeutic options for these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08427-x","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T08:03:07Z","timestamp":1623139387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuan-jun","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-feng","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"issue":"5","key":"8427_CR1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/CCO.0000000000000104","volume":"26","author":"MA Nobbenhuis","year":"2014","unstructured":"Nobbenhuis MA, Lalondrelle S, Larkin J, et al. Management of melanomas of the gynaecological tract. Curr Opin Oncol. 2014;26(5):508\u201313. https:\/\/doi.org\/10.1097\/CCO.0000000000000104.","journal-title":"Curr Opin Oncol"},{"key":"8427_CR2","doi-asserted-by":"publisher","first-page":"166. e 7","DOI":"10.1016\/j.urolonc.2015.11.009","volume":"34","author":"A Sanchez","year":"2016","unstructured":"Sanchez A, Rodriguez D, Allard CB, et al. Primary genitourinary melanoma: epidemiology and disease-specific survival in a large population-based cohort. Urol Oncol. 2016;34:166. e 7\u2013166.e14.","journal-title":"Urol Oncol"},{"issue":"8","key":"8427_CR3","first-page":"739","volume":"5","author":"M Mihajlovic","year":"2012","unstructured":"Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol. 2012;5(8):739\u201353.","journal-title":"Int J Clin Exp Pathol"},{"key":"8427_CR4","doi-asserted-by":"crossref","unstructured":"Gadducci A, Carinelli S, Guerrieri ME, et al. Melanoma of the lower genital tract: Prognostic factors and treatment modalities. Gynecol Oncol. 2018;150(1):180\u20139.","DOI":"10.1016\/j.ygyno.2018.04.562"},{"issue":"1","key":"8427_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2013.09.007","volume":"50","author":"M Del Vecchio","year":"2014","unstructured":"Del Vecchio M, Di Guardo L, Ascierto PA, et al. Efficacy and safety of ipilimumab 3 mg\/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer. 2014;50(1):121\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2013.09.007.","journal-title":"Eur J Cancer"},{"key":"8427_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-3-319-22539-5_13","volume":"167","author":"KR Spencer","year":"2016","unstructured":"Spencer KR, Mehnert JM. Mucosal melanoma: epidemiology, biology and treatment. Cancer Treat Res. 2016;167:295\u2013320. https:\/\/doi.org\/10.1007\/978-3-319-22539-5_13.","journal-title":"Cancer Treat Res"},{"issue":"3","key":"8427_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/path.4204","volume":"230","author":"SJ Furney","year":"2013","unstructured":"Furney SJ, Turajlic S, Stamp G, Nohadani M, Carlisle A, Thomas JM, et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol. 2013;230(3):261\u20139. https:\/\/doi.org\/10.1002\/path.4204.","journal-title":"J Pathol"},{"issue":"20","key":"8427_CR8","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135\u201347. https:\/\/doi.org\/10.1056\/NEJMoa050092.","journal-title":"N Engl J Med"},{"issue":"6892","key":"8427_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354. https:\/\/doi.org\/10.1038\/nature00766.","journal-title":"Nature"},{"issue":"10","key":"8427_CR10","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/modpathol.2013.211","volume":"27","author":"S Aulmann","year":"2014","unstructured":"Aulmann S, Sinn HP, Penzel R, Gilks CB, Schott S, Hassel JC, et al. Comparison of molecular abnormalities in vulvar and vaginal melanomas. Mod Pathol. 2014;27(10):1386\u201393. https:\/\/doi.org\/10.1038\/modpathol.2013.211.","journal-title":"Mod Pathol"},{"issue":"10","key":"8427_CR11","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1158\/1078-0432.CCR-03-0562","volume":"10","author":"Y Cohen","year":"2004","unstructured":"Cohen Y, Rosenbaum E, Begum S, Goldenberg D, Esche C, Lavie O, et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res. 2004;10(10):3444\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0562.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8427_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2014.04.056","volume":"134","author":"AC van Engen-van Grunsven","year":"2014","unstructured":"van Engen-van Grunsven AC, Kusters-Vandevelde HV, De Hullu J, et al. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract\u2013a study of 24 cases from the Netherlands. Gynecol Oncol. 2014;134(1):10\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2014.04.056.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"8427_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1600-0463.2011.02737.x","volume":"119","author":"J Yun","year":"2011","unstructured":"Yun J, Lee J, Jang J, et al. KIT amplification and gene mutations in acral\/mucosal melanoma in Korea. APMIS. 2011;119(6):330\u20135. https:\/\/doi.org\/10.1111\/j.1600-0463.2011.02737.x.","journal-title":"APMIS"},{"issue":"12","key":"8427_CR14","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/sj.bjc.6604791","volume":"99","author":"I Satzger","year":"2008","unstructured":"Satzger I, Schaefer T, Kuettler U, Broecker V, Voelker B, Ostertag H, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Brit J Cancer. 2008;99(12):2065\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6604791.","journal-title":"Brit J Cancer"},{"issue":"2","key":"8427_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jaad.2014.03.033","volume":"71","author":"D Tseng","year":"2014","unstructured":"Tseng D, Kim J, Warrick A, Nelson D, Pukay M, Beadling C, et al. Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. J Am Acad Dermato. 2014;71(2):229\u201336. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.033.","journal-title":"J Am Acad Dermato"},{"issue":"22","key":"8427_CR16","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1001\/jama.2011.746","volume":"305","author":"RD Carvajal","year":"2011","unstructured":"Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. Jama. 2011;305(22):2327\u201334. https:\/\/doi.org\/10.1001\/jama.2011.746.","journal-title":"Jama"},{"issue":"4","key":"8427_CR17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/jmg.2003.016667","volume":"41","author":"RH Edwards","year":"2004","unstructured":"Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet. 2004;41(4):270\u20132. https:\/\/doi.org\/10.1136\/jmg.2003.016667.","journal-title":"J Med Genet"},{"issue":"21","key":"8427_CR18","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","volume":"14","author":"C Beadling","year":"2008","unstructured":"Beadling C, Jacobson-Dunlop E, Hodi FS, le C, Warrick A, Patterson J, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14(21):6821\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0575.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"8427_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11912-012-0244-x","volume":"14","author":"MA Postow","year":"2012","unstructured":"Postow MA, Hamid O, Carvajal RD. Mucosal melanoma: pathogenesis, clinical behavior, and management. Curr Oncol Rep. 2012;14(5):441\u20138. https:\/\/doi.org\/10.1007\/s11912-012-0244-x.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"8427_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/CMR.0000000000000345","volume":"27","author":"JD Hintzsche","year":"2017","unstructured":"Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, et al. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res. 2017;27(3):189\u201399. https:\/\/doi.org\/10.1097\/CMR.0000000000000345.","journal-title":"Melanoma Res"},{"issue":"7653","key":"8427_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175\u201380. https:\/\/doi.org\/10.1038\/nature22071.","journal-title":"Nature"},{"issue":"1","key":"8427_CR22","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019;10(1):3163\u201378. https:\/\/doi.org\/10.1038\/s41467-019-11107-x.","journal-title":"Nat Commun"},{"issue":"12","key":"8427_CR23","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1158\/1078-0432.CCR-18-3442","volume":"25","author":"R Zhou","year":"2019","unstructured":"Zhou R, Shi C, Tao W, Li J, Wu J, Han Y, et al. Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations. Clin Cancer Res. 2019;25(12):3548\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3442.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8427_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1746-1596-8-87","volume":"8","author":"B Schilling","year":"2013","unstructured":"Schilling B, Bielefeld N, Sucker A, et al. Lack of SF3B1 R625 mutations in cutaneous melanoma. Diagn Pathol. 2013;8(1):87.","journal-title":"Diagn Pathol"},{"issue":"9","key":"8427_CR25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.18632\/oncotarget.26584","volume":"10","author":"C Quek","year":"2019","unstructured":"Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, et al. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget. 2019;10(9):930\u201341. https:\/\/doi.org\/10.18632\/oncotarget.26584.","journal-title":"Oncotarget"},{"issue":"12","key":"8427_CR26","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1158\/1078-0432.CCR-10-2917","volume":"17","author":"K Omholt","year":"2011","unstructured":"Omholt K, Grafstrom E, Kanter-Lewensohn L, et al. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res. 2011;17(12):3933\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2917.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"8427_CR27","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/cncr.30473","volume":"123","author":"JY Hou","year":"2016","unstructured":"Hou JY, Baptiste C, Hombalegowda RB, Tergas AI, Feldman R, Jones NL, et al. Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. Cancer. 2016;123(8):1333\u201344. https:\/\/doi.org\/10.1002\/cncr.30473.","journal-title":"Cancer"},{"issue":"4","key":"8427_CR28","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/LGT.0000000000000142","volume":"19","author":"M Rouzbahman","year":"2015","unstructured":"Rouzbahman M, Kamel-Reid S, Al Habeeb A, et al. Malignant melanoma of vulva and vagina: a Histomorphological review and mutation analysis-a single-center study. J Low Genit Tract Dis. 2015;19(4):350\u20133. https:\/\/doi.org\/10.1097\/LGT.0000000000000142.","journal-title":"J Low Genit Tract Dis"},{"issue":"6","key":"8427_CR29","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/jcp.2004.022509","volume":"58","author":"CW Wong","year":"2005","unstructured":"Wong CW, Fan YS, Chan TL, Chan AS, Ho LC, Ma TK, et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol. 2005;58(6):640\u20134. https:\/\/doi.org\/10.1136\/jcp.2004.022509.","journal-title":"J Clin Pathol"},{"key":"8427_CR30","first-page":"4682","volume":"49","author":"JL Bos","year":"1989","unstructured":"Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682\u20139.","journal-title":"Cancer Res"},{"issue":"17","key":"8427_CR31","first-page":"6483","volume":"9","author":"K Omholt","year":"2003","unstructured":"Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9(17):6483\u20138.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8427_CR32","first-page":"883","volume":"149","author":"A Van Elsas","year":"1996","unstructured":"Van Elsas A, Zerp SF, van der Flier S, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol. 1996;149(3):883\u201393.","journal-title":"Am J Pathol"},{"issue":"5","key":"8427_CR33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00428-009-0762-6","volume":"454","author":"S Sekine","year":"2009","unstructured":"Sekine S, Nakanishi Y, Ogawa R, Kouda S, Kanai Y. Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites. Virchows Arch. 2009;454(5):513\u20137. https:\/\/doi.org\/10.1007\/s00428-009-0762-6.","journal-title":"Virchows Arch"},{"issue":"3","key":"8427_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CML, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(13)70024-X.","journal-title":"Lancet Oncol"},{"issue":"3","key":"8427_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","volume":"3","author":"O Maertens","year":"2013","unstructured":"Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013;3(3):338\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0313.","journal-title":"Cancer Discov"},{"issue":"10","key":"8427_CR36","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","volume":"3","author":"SJ Furney","year":"2013","unstructured":"Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013;3(10):1122\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0330.","journal-title":"Cancer Discov"},{"issue":"15","key":"8427_CR37","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384\u201395. https:\/\/doi.org\/10.1056\/NEJMoa1103283.","journal-title":"N Engl J Med"},{"issue":"7403","key":"8427_CR38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature11143","volume":"486","author":"MJ Ellis","year":"2012","unstructured":"Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353\u201360. https:\/\/doi.org\/10.1038\/nature11143.","journal-title":"Nature"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08427-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08427-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08427-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T08:04:45Z","timestamp":1623139485000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08427-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8427"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08427-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in accordance with the Declaration of Helsinki and written informed consent was obtained from the patients or their legal guardians. The study protocol was approved by the institutional review boards of Fujian Cancer Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"677"}}